Stock market today: S&P 500 drops for fifth day as focus shifts to Powell’s speech
Shalom Auerbach, a principal at Einodmil LLC and a significant shareholder of OS Therapies Inc (NASDAQ:OSTX), recently sold a substantial portion of common stock in the company. According to a recent SEC filing, Auerbach disposed of 60,012 shares in two separate transactions on April 9 and April 10, 2025. The timing of these sales is notable, as InvestingPro data shows the stock has declined over 70% year-to-date and currently trades at $1.25.
The sales were executed at prices ranging from $1.353 to $1.39 per share, totaling $81,566. Following these transactions, Auerbach, through Einodmil LLC, holds 2,746,199 shares of OS Therapies Inc, representing a significant portion of the company’s $24.26 million market capitalization. It’s noteworthy that Auerbach has voting and dispositive power over the shares held by Einodmil, although he disclaims beneficial ownership beyond his financial interest in the shares. According to InvestingPro, analyst price targets for OSTX range from $6 to $20, suggesting potential upside despite recent market performance.
These transactions are part of regular trading activities and provide insight into the trading behavior of significant shareholders in OS Therapies Inc. The company maintains a "FAIR" Financial Health score according to InvestingPro, which offers additional insights through 8 more key ProTips about the company’s financial position and market performance.
In other recent news, OS Therapies Inc has received shareholder approval for a significant stock issuance, as detailed in a regulatory filing with the Securities and Exchange Commission. This approval allows the company to issue shares of common stock upon conversion of Series A Senior Convertible Preferred Stock and the exercise of certain warrants, potentially exceeding 20% of the company’s outstanding common stock. Additionally, OS Therapies announced the acquisition of cancer immunotherapy assets from Ayala Pharmaceuticals, expanding its clinical pipeline with new candidates targeting various cancer types. The company’s lead asset, OST-HER2, has shown positive results in a Phase 2b clinical trial for osteosarcoma and is preparing for a Biologics License Application submission to the FDA in 2025.
OS Therapies has also established a new subsidiary, OS Drug Conjugates, to leverage its patented platforms for tunable antibody drug conjugates. This strategic move aims to enhance shareholder value through potential joint ventures with clinical-stage therapeutics companies. Furthermore, OS Therapies is advancing regulatory discussions for OST-HER2 with agencies like the FDA and the European Medicines Agency, aiming for accelerated approval. The company has postponed a Special Meeting of Stockholders due to a lack of quorum, rescheduling it for April 9, 2025. These developments reflect OS Therapies’ ongoing efforts to strengthen its position in the oncology field and improve treatment outcomes for patients.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.